Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: A subgroup analysis of ROCKET AF

Grants

Funding Acknowledgements

Funding Johnson and Johnson Pharmaceutical Research and Development and Bayer HealthCare.GJH has received honoraria for serving on trial executive committees for Johnson and Johnson, Bayer, and Sanofi-Aventis; and on trial adjudication committees and an advisory board for Boehringer Ingelheim. MRP has received honoraria for serving on executive committees for Johnson and Johnson and Bayer, has received consulting fees from Ortho McNeil Janssen and Bayer HealthCare, and has served on an advisory board for Genzyme. RCB has received research support from Bayer and Johnson and Johnson. GB has received honoraria for serving on a steering committee for Johnson and Johnson and Bayer and has received fees for serving on advisory boards for Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, and Sanofi-Aventis. AC has received honoraria as a member of a steering committee for Johnson and Johnson and Bayer, and for participation in clinical trials, contributions to advisory boards, or oral presentations from Sanofi-Aventis, Bristol-Myers Squibb, Solvay, Abbott, and Pfizer. H-CD has received honoraria for participation in clinical trials, contribution to advisory boards, or oral presentations from Abbott, Allergan, AstraZeneca, Bayer Vital, Bristol-Myers Squibb, Boehringer Ingelheim, CoAxia, D-Pharm, EV3, Fresenius, GlaxoSmithKline, Janssen Cilag, Knoll, MSD, Medtronic, MindFrame, Neurobiological Technologies, Novartis, Novo-Nordisk, Paion, Parke-Davis, Pfizer, Sanofi-Aventis, Sankyo, Schering-Plough, Servier, Solvay, Thrombogenics, Wyeth, and Yamaguchi; and H-CD's institution has received financial support for research projects from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Lundbeck, Novartis, Janssen-Cilag Sanofi-Aventis, Syngis, and Talecris. GAD has acted on an advisory board for Boehringer Ingelheim. JLH has received honoraria for serving on a steering committee for Johnson and Johnson and Bayer and fees for advisory activities for Boehringer Ingelheim, Bristol-Myers Squibb, and Pfizer. KWM has received grant support from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Johnson and Johnson, Merck, Momenta Pharmaceuticals, Novartis, Portola, Pozen, Regado Biotechnologies, Sanofi-Aventis, Schering-Plough (now Merck), and The Medicines Company; and consulting fees from AstraZeneca, Johnson and Johnson, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Ortho/McNeill, Pfizer, Polymedix, Sanofi-Aventis, and Schering-Plough (now Merck). J-LM has received honoraria for serving on a steering committee for Johnson and Johnson and Bayer and fees for serving on advisory boards for Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, and Pfizer. BN has received consultancy payments from Bayer, payment for lectures from Allergan and Bayer, and royalties for a book published by Karolinska University Press. BN's institution has received honoraria for consultancy from Syngis, Servier, Bayer, PhotoThera, and Boehringer Ingelheim. CCN is an employee of Johnson and Johnson Pharmaceutical Research and Development (Raritan, NJ, USA) and owns stock in Johnson and Johnson. JFP is a former employee of Bayer HealthCare. ROR has received honoraria as a member of a steering committee from Johnson and Johnson and Bayer and for participating in clinical trials, contributions to advisory boards, or oral presentations from Bayer, Boehringer Ingelheim, Servier, Lundbeck, and Schering.DES has received honoraria for serving on advisory boards or payments for consulting, or both from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Johnson and Johnson, Pfizer, and Sanofi. LW has received honoraria as a member of a steering committee for Johnson and Johnson and Bayer, and for participation in clinical trials, contributions to advisory boards, or oral presentations from Sanofi-Aventis, Bristol-Myers Squibb, Boehringer Ingelheim, and Pfizer. RMC has received consulting fees and research funding from Johnson and Johnson; all other industry interactions are listed at www.dcri.org. KAAF has received grants and honoraria from Bayer, Lilly, Boehringer Ingelheim, Sanofi-Aventis, and GlaxoSmithKline. WH has received honoraria for serving on an executive committee for Johnson and Johnson and Bayer and advisory board fees from Boehringer Ingelheim. SRS and AM declare that they have no conflicts of interest.